Navigation Links
BioMS Medical warrant extension
Date:3/2/2009

Toronto Stock Exchange Symbol: MS

EDMONTON, March 2 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), announced that effective on March 16, 2009 the exercise term of 11,500,000 share purchase warrants, each of which entitles the holder to purchase one Class A common share at a price of $5.00 per share, will be extended from March 23, 2009 to December 31, 2009.

On March 18, 2008, BioMS Medical's Board of Directors passed a resolution to extend 10,514,000 of the warrants, the portion held by warrant holders who are at arm's length to the Company. At the Company's annual general meeting held on May 9, 2008, the shareholders holding a majority of the Class A common shares, excluding the votes attached to Class A common shares held by insiders whose warrants were being amended, approved the extension for the remaining 986,000 warrants held by insiders.

About BioMS Medical Corp.

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to dirucotide in exchange for an $87 million upfront payment, milestone payments and escalating royalties on sales. For further information please visit our website at www.biomsmedical.com.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medical to present at BIO CEO & Investor Conference
10. BioMS Medical Announces 2007 Year End Results
11. BioMS Medical to present at BioCentury Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... Madison, WI (PRWEB) April 17, 2015 ... provide sales and marketing support for the powerful ... at the Chemical Genomics Center at the Lankenau ... LCGC’s mission is to measurably improve successful ... to HTS, by offering rare, drug-like libraries available ...
(Date:4/16/2015)... CAMBRIDGE, Mass. (PRWEB) April 16, 2015 ... of smart data solutions driven by Semantic Web ... provider of specialist information and services for the ... today announced that its joint solution ‘Smart Data ... named a finalist for the 2015 Bio-IT ‘Best ...
(Date:4/16/2015)... Irvine, CA (PRWEB) April 16, 2015 ... in the Buzz of BIO Contest for ... Industry Organization (BIO), the 2015 BIO International Convention will ... in Philadelphia, Pennsylvania. During the Buzz of BIO contest, ... like to see present at the conference. The community ...
(Date:4/16/2015)... According to the 2014 Liberty Mutual ... was ranked first among the leading causes of ... pushing, pulling, holding, carrying, or throwing and cost ... Round Company takes statistics like this very seriously. ... develop and design equipment that prevents these injuries ...
Breaking Biology Technology:BellBrook Labs and Lankenau Institute Partner to Accelerate Drug Discovery using Orthogonal Pooled Screening 2Cambridge Semantics and Informa Named Bio-IT Award Finalist for Smart Data Lake Solution for Clinical Trial and Competitive Intelligence 2Cambridge Semantics and Informa Named Bio-IT Award Finalist for Smart Data Lake Solution for Clinical Trial and Competitive Intelligence 3Proove Bisociences to Participate in the Buzz of BIO at the 2015 BIO International Convention 2Proove Bisociences to Participate in the Buzz of BIO at the 2015 BIO International Convention 3The David Round Company Helps Companies Meet OSHA Standards by Combining Safety, Ergonomics, and Productivity 2
... 7 /PRNewswire-FirstCall/ - ARIUS Research Inc., (TSX:,ARI), a ... of,antibody therapeutics, today announced that it will deliver ... for,two of its anti-cancer antibody drug candidates. ... Francisco on September 7-8,Arius will report recent results ...
... Announces ofatumumab Appeared More Effective Than rituximab ... ... Genmab A/S,(OMX: GEN) announced today that ofatumumab (HuMax-CD20(R)) appeared more,effective ... than rituximab in a pre-clinical study. The CD20,antibodies were incubated ...
... Feynman presented a talk entitled There,s Plenty of Room at ... reason why humans couldn,t manipulate atoms. However, if atomic ... positions remains. How do you know what you have ... of Science, IBM and Imago have taken a seminal step ...
Cached Biology Technology:Arius Features Preclinical Data on Antibody Candidates at Two Conferences 2Arius Features Preclinical Data on Antibody Candidates at Two Conferences 3Genmab Announces Encouraging Preclinical Data for ofatumumab 2IBM and Imago find a crucial difficulty in semiconductor device scaling 2
(Date:4/14/2015)... Conn. , April 14, 2015 NXT-ID, ... a biometric authentication company focused on the growing mobile ... been nominated for the 2015 New York Design Awards ... The Design100, New York City Design Awards are part ... based on over 2,500 ratings from the marketplace, industry ...
(Date:4/13/2015)... April 13, 2015  higi, a leading cloud-based consumer ... more fully engage with their communities around health and ... protected and secure API.  ... most accessible, affordable, and convenient vehicle to receive validated ... The API will allow higi,s trusted ...
(Date:4/9/2015)... SAN JOSE, Calif. , April 9, 2015 /PRNewswire/ ... of human interface solutions, announced today that it will ... 2015 on Thursday, April 23, 2015, after the close ... call for analysts and investors at 2:00 p.m. PT ... information.    To participate on the live ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3Synaptics to Report Third Quarter Results on April 23 2
... 2013 -- Resveratrol, a naturally occurring polyphenol compound produced ... found in red wine, has been touted as a ... This has been supported by some experimental studies, whereas ... using two multiple sclerosis (MS) models published in ...
... metabolic pathway for breaking down glucose that could lead to ... The new pathway is intended to replace the ... reactions that nearly all organisms use to convert sugars into ... the six carbon atoms found in glucose into two-carbon molecules ...
... a diverse team of University of Pittsburgh scientists to report ... that they had solved the mystery of a basic ... mechanism by which mitochondria tiny structures inside cells often ... and need to be eliminated, the Pitt team has opened ...
Cached Biology News:Resveratrol, found in red wine, worsens MS-like symptoms and neuropathology in mice 2Resveratrol, found in red wine, worsens MS-like symptoms and neuropathology in mice 3UCLA engineers develop new metabolic pathway to more efficiently convert sugars into biofuels 2When cells 'eat' their own power plants; Pitt scientists solve mystery of cellular process 2When cells 'eat' their own power plants; Pitt scientists solve mystery of cellular process 3
Mouse Endoglin/CD105 Fluorescein MAb (Clone 209701)...
... is an inhibitor of ... concentration of inhibitor required ... must be determined empirically ... micromolar inhibitor is sufficient ...
...
SNARE associated protein snapin, clone MGC:2717...
Biology Products: